Eli Lilly to Acquire Ajax Therapeutics in $2.3B Oncology Deal

INDIANAPOLIS, NEW YORK & CAMBRIDGE, Mass., April 27, 2026

Eli Lilly and Company has announced a definitive agreement to acquire Ajax Therapeutics in a deal valued at up to $2.3 billion, aiming to strengthen its oncology pipeline and accelerate the development of innovative therapies for myelofibrosis and polycythemia vera. The acquisition underscores a strategic push toward advancing next-generation targeted treatments in hematologic malignancies, with a particular focus on improving durability and patient outcomes.

Strategic Expansion in Blood Cancer Therapeutics

The acquisition significantly enhances Lilly’s oncology capabilities by integrating Ajax’s novel JAK2 inhibitor program into its pipeline, reinforcing its long-term commitment to treating myeloproliferative neoplasms (MPNs). Ajax’s lead candidate, AJ1-11095, represents a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, offering a differentiated mechanism compared to existing therapies. Unlike approved JAK inhibitors that bind to the Type I conformation, AJ1-11095 targets the Type II conformation, potentially enabling deeper and more durable disease control for patients who often develop resistance or lose response to current treatments.

This strategic move aligns with Lilly’s broader oncology vision, leveraging its expertise in drug development, clinical execution, and commercialization to accelerate Ajax’s investigational therapy into later-stage trials. The company expects clinical proof-of-concept data in 2026, with plans to rapidly advance the candidate into registrational clinical studies, positioning it as a potential breakthrough in hematologic cancer care.

Innovative Science Driving Next-Generation Therapies

AJ1-11095 is designed to overcome key limitations of existing therapies by targeting resistance mechanisms in JAK2 signaling, a critical pathway in MPNs such as myelofibrosis and polycythemia vera. Current treatments, while effective in symptom control, often fail to deliver sustained benefits, leading to discontinuation in many patients. The novel binding approach of AJ1-11095 could provide a new therapeutic option for patients who have exhausted existing JAK inhibitor treatments, addressing a significant unmet medical need.

The drug is administered as a once-daily oral therapy, enhancing patient convenience and adherence while maintaining strong efficacy potential. The ongoing Phase 1 study, initiated in late 2024, is expected to determine optimal dosing for future trials, marking a critical step in its clinical development pathway.

Financial and Regulatory Framework of the Deal

Under the terms of the agreement, Ajax shareholders may receive up to $2.3 billion in total consideration, including an upfront payment and additional milestone-based payments tied to clinical and regulatory achievements. The transaction remains subject to customary closing conditions, including regulatory approval under the Hart-Scott-Rodino Act, ensuring compliance with antitrust regulations.

The deal reflects a broader industry trend of large pharmaceutical companies acquiring innovative biotech firms to strengthen pipelines, particularly in oncology, where precision medicine and targeted therapies are rapidly evolving. By integrating Ajax’s scientific expertise and computational drug discovery capabilities, Lilly aims to accelerate innovation and deliver transformative therapies to patients worldwide.

Implications for Patients and the Pharma Industry

This acquisition highlights a critical shift toward next-generation targeted therapies in oncology, emphasizing the importance of overcoming resistance mechanisms and improving long-term disease management. For patients with myelofibrosis and polycythemia vera, the development of more durable and effective treatments could significantly improve quality of life and clinical outcomes.

From a cGxP perspective, the deal underscores the importance of robust clinical development, regulatory strategy, and manufacturing readiness, as Lilly prepares to advance AJ1-11095 through the clinical pipeline. The integration of innovative biotech assets into large-scale pharmaceutical operations also reinforces the need for strict compliance with GMP, GCP, and regulatory standards throughout the drug development lifecycle.

Source: Eli Lilly, Ajax Therapeutics press release